Stocktoria
Ultragenyx Pharmaceutical Inc. RARE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-01-31
Ultragenyx Pharmaceutical Inc. statistics & valuation
Market cap$3.0B
P / S4.5×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -79.5% | -95.7% | -131.1% | -178.6% | -108.6% |
| Net margin | -85.4% | -101.6% | -139.9% | -194.7% | -129.2% |
| FCF margin | -70.1% | -75.2% | -119.6% | -136.7% | -117.2% |
| Return on assets | -37.5% | -37.9% | -40.7% | -45.8% | -29.8% |
| Return on equity | 718.8% | -223.1% | -220.7% | -201.0% | -49.2% |
| Current ratio | 2.48 | 2.38 | 2.61 | 3.38 | 4.72 |
| Revenue growth | 20.2% | 29.0% | 19.5% | 3.4% | 29.7% |
Source: SEC EDGAR filings · CIK 0001515673 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.